Home  >  Media Statements
Share

Media Statements

July 23, 2019
PARSIPPANY, N.J - July 23, 2019 – Zoetis is aware of a video circulating on social media that references Simparica ® (sarolaner) Chewables and a potential neurologic adverse event in a dog in the U.S. Since coming to the attention of Zoetis, the company has offered the following response to inquiries: At Zoetis, we are committed to providing safe and effective products to veterinarians, pet owners and the animals in their care. Many Zoetis colleagues own pets themselves, and we can all sympathize with the frustration and concern that pet owners experience when their pets are sick. We have been in contact with the pet owner in this video to better understand the situation. Simparica is one of four tick and flea medications for dogs in the isoxazoline class currently on the market. The labeling for Simparica is approved by the FDA. The product label and all related promotional materials have always included information about neurologic signs such as tremors, unsteadiness, and/or ...
February 17, 2017
PARSIPPANY, N.J.  – Feb. 17, 2017 - We at Zoetis are pleased that the European Medicines Agency, Committee for Veterinary Products for Medicinal Use, adopted a positive opinion for Cytopoint™ at their February meeting. Upon full approval, Cytopoint would become the first monoclonal antibody licensed for veterinary use in the European Union. It is indicated for the treatment of clinical manifestations of atopic dermatitis in dogs. Lokivetmab, the active substance in Cytopoint, is a caninised monoclonal antibody that specifically targets canine interleukin-31, a key cytokine in canine atopic dermatitis. We look forward to the decision of the European Commission on our application for marketing authorization of Cytopoint. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and ...
June 2, 2015
Today the U.S. Food and Drug Administration published the finalized Veterinary Feed Directive (VFD). This regulation mandates the rules and responsibilities of licensed veterinarians in prescribing and administering medically important antibiotics in feed. We are reviewing the Veterinary Feed Directive in detail. We support the intent of the Veterinary Feed Directive (VFD) regulation to guide veterinarians and farmers as they manage the health and welfare of animals. We believe that veterinarians should be involved in decisions regarding antibiotic use in food animals for the health of the animal and for the safety of the food supply. Zoetis is committed to supporting our veterinary and livestock producer customers to make a successful transition to the new procedures outlined in the VFD. Zoetis continues to remove growth promotion uses of medically important antibiotics now that the VFD regulation is finalized. These updates to the VFD were made in conjunction with ...
December 11, 2013
Today the U.S. Food and Drug Administration finalized Guidance #213 establishing the procedures for voluntarily phasing out growth promotion indications for medically important antibiotics in alignment with Guidance #209 and published proposed changes to the Veterinary Feed Directive (VFD) regulation. The VFD regulation mandates the rules and responsibilities of licensed veterinarians in prescribing and administering medically important antibiotics in feed.   Guidance #209 establishes two voluntary principles: The use of medically important antimicrobial drugs in food-producing animals should be limited to uses that are considered necessary for assuring animal health. The use of medically important antimicrobial drugs in food-producing animals should include veterinary oversight or consultation. Guidance #213 provides the procedures for voluntarily phasing out growth promotion indications and establishing therapeutic treatment indications for the use ...
May 20, 2013
MADISON, NJ - May 20, 2013 –Zoetis Inc. (NYSE: ZTS) acknowledges that the European Commission started a procedure under Article 45 of Regulation (EC) No. 726/2004 regarding the EU marketing authorization for Suvaxyn PCV, a centrally-authorized vaccine against Porcine Circovirus 2 in swine. As part of this procedure, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Veterinary Use (CVMP) discussed the issue during its latest monthly meeting (14-16 May 2013) . The initiation of the above procedure follows Zoetis’ proactive decision, on 25 March 2013, to stop the distribution of two batches of Suvaxyn PCV as a result of higher than expected adverse reactions, reported mainly in Spain. The two batches were later recalled by Zoetis, following subsequent discussions with the Spanish authorities and the EMA. Zoetis continues to investigate the potential root cause for the reported adverse reactions and is committed to working with the EMA, the European Commission, ...